Glenmark Pharmaceuticals has announced the receipt of US Food and Drug Administration (FDA) approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray.

The company's Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC, and will be distributed in the US by Glenmark Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of approximately USD 295.2 million.

Commenting on the approval, Marc Kikuchi, President and Business Head, North America, said, “The approval of Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray marks another step in expanding our respiratory portfolio in the US and builds on the strong foundation we have established in this therapeutic area. We remain committed to broadening access to quality, affordable treatment options that address the evolving needs of patients and healthcare providers.”